Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review.
biologic
biomarker
nitric oxide
severe asthma
Journal
Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
received:
25
12
2022
revised:
02
02
2023
accepted:
03
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Fractional exhaled nitric oxide (FeNO) is a biomarker of airway inflammation associated with airway hyper-responsiveness and type-2 inflammation. Its role in the management of severe asthmatic patients undergoing biologic treatment, as well as FeNO dynamics during biologic treatment, is largely unexplored. The aim was to evaluate published data contributing to the following areas: (1) FeNO as a predictive biomarker of response to biologic treatment; (2) the influence of biologic treatment in FeNO values; (3) FeNO as a biomarker for the prediction of exacerbations in patients treated with biologics. The systematic search was conducted on the Medline database through the Pubmed search engine, including all studies from 2009 to the present. Higher baseline values of FeNO are associated with better clinical control in patients treated with omalizumab, dupilumab, and tezepelumab. FeNO dynamics during biologic treatment highlights a clear reduction in FeNO values in patients treated with anti-IL4/13 and anti-IL13, as well as in patients treated with tezepelumab. During the treatment, FeNO may help to predict clinical worsening and to differentiate eosinophilic from non-eosinophilic exacerbations. Higher baseline FeNO levels appear to be associated with a greater benefit in terms of clinical control and reduction of exacerbation rate, while FeNO dynamics during biologic treatment remains a largely unexplored issue since few studies have investigated it as a primary outcome. FeNO remains detectable during biologic treatment, but its potential utility as a biomarker of clinical control is still unclear and represents an interesting research area to be developed.
Sections du résumé
BACKGROUND
BACKGROUND
Fractional exhaled nitric oxide (FeNO) is a biomarker of airway inflammation associated with airway hyper-responsiveness and type-2 inflammation. Its role in the management of severe asthmatic patients undergoing biologic treatment, as well as FeNO dynamics during biologic treatment, is largely unexplored.
PURPOSE
OBJECTIVE
The aim was to evaluate published data contributing to the following areas: (1) FeNO as a predictive biomarker of response to biologic treatment; (2) the influence of biologic treatment in FeNO values; (3) FeNO as a biomarker for the prediction of exacerbations in patients treated with biologics.
METHODS
METHODS
The systematic search was conducted on the Medline database through the Pubmed search engine, including all studies from 2009 to the present.
RESULTS
RESULTS
Higher baseline values of FeNO are associated with better clinical control in patients treated with omalizumab, dupilumab, and tezepelumab. FeNO dynamics during biologic treatment highlights a clear reduction in FeNO values in patients treated with anti-IL4/13 and anti-IL13, as well as in patients treated with tezepelumab. During the treatment, FeNO may help to predict clinical worsening and to differentiate eosinophilic from non-eosinophilic exacerbations.
CONCLUSIONS
CONCLUSIONS
Higher baseline FeNO levels appear to be associated with a greater benefit in terms of clinical control and reduction of exacerbation rate, while FeNO dynamics during biologic treatment remains a largely unexplored issue since few studies have investigated it as a primary outcome. FeNO remains detectable during biologic treatment, but its potential utility as a biomarker of clinical control is still unclear and represents an interesting research area to be developed.
Identifiants
pubmed: 36829959
pii: antiox12020400
doi: 10.3390/antiox12020400
pmc: PMC9952501
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Lancet Respir Med. 2014 Nov;2(11):879-890
pubmed: 25306557
J Allergy Clin Immunol. 2017 Oct;140(4):1130-1137.e5
pubmed: 28238748
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841274
pubmed: 31002021
Lancet Respir Med. 2018 Jul;6(7):511-525
pubmed: 29792288
Immun Inflamm Dis. 2018 Sep;6(3):382-391
pubmed: 29737044
N Engl J Med. 2017 Sep 7;377(10):936-946
pubmed: 28877011
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1308-1312
pubmed: 31298922
Ann Transl Med. 2020 Apr;8(7):438
pubmed: 32395482
Allergy. 2009 Dec;64(12):1728-36
pubmed: 19839977
PLoS One. 2017 Aug 31;12(8):e0183869
pubmed: 28859150
Pediatrics. 2004 Apr;113(4):e308-12
pubmed: 15060258
Scand J Immunol. 2020 Jan;91(1):e12835
pubmed: 31596502
Ann Allergy Asthma Immunol. 2021 Jan;126(1):102-104
pubmed: 32920056
Expert Rev Respir Med. 2019 Dec;13(12):1205-1212
pubmed: 31592700
Allergy. 2022 Jun;77(6):1786-1796
pubmed: 34913186
Asia Pac Allergy. 2021 Jul 16;11(3):e31
pubmed: 34386407
J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1
pubmed: 29800752
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Sci Rep. 2021 Mar 9;11(1):5453
pubmed: 33750842
J Asthma Allergy. 2021 May 27;14:575-583
pubmed: 34079295
Multidiscip Respir Med. 2022 Feb 04;17(1):797
pubmed: 35280851
Lancet Respir Med. 2018 Jul;6(7):499-510
pubmed: 29793857
Adv Med Sci. 2011;56(2):318-22
pubmed: 21940268
J Asthma Allergy. 2021 Jul 12;14:863-871
pubmed: 34285513
Thorax. 2017 Feb;72(2):109-116
pubmed: 27388487
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
BMC Pulm Med. 2020 Jun 29;20(1):184
pubmed: 32600318
J Asthma. 2020 Jan;57(1):79-81
pubmed: 30821528
Respir Med. 2020 Sep;171:106080
pubmed: 32917354
J Allergy Clin Immunol Pract. 2022 Nov;10(11):2916-2924.e4
pubmed: 36028446
N Engl J Med. 2022 Jan 13;386(2):157-171
pubmed: 35020986
Clin Ther. 2019 Oct;41(10):1956-1971
pubmed: 31563391
Lancet Respir Med. 2021 Oct;9(10):1174-1184
pubmed: 33971168
J Asthma Allergy. 2020 Dec 16;13:701-711
pubmed: 33364789
Expert Rev Respir Med. 2022 Sep;16(9):1023-1033
pubmed: 35730466
J Asthma Allergy. 2021 Feb 22;14:163-173
pubmed: 33654413
N Engl J Med. 2011 Sep 22;365(12):1088-98
pubmed: 21812663
Ann Allergy Asthma Immunol. 2005 Nov;95(5):443-51
pubmed: 16312167
Int Arch Allergy Immunol. 2020;181(8):606-612
pubmed: 32516771
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
Can Respir J. 2019 Dec 1;2019:8607657
pubmed: 31885750
Clin Ther. 2021 Jun;43(6):e192-e208
pubmed: 33962763
Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11
pubmed: 23471469
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
J Invest Dermatol. 2021 Aug;141(8):1943-1953.e13
pubmed: 33610558
PLoS One. 2021 Mar 11;16(3):e0248305
pubmed: 33705484
J Allergy Clin Immunol Pract. 2021 May;9(5):2093-2096.e1
pubmed: 33486140
Clinicoecon Outcomes Res. 2019 Apr 17;11:301-307
pubmed: 31114270
J Asthma. 2020 Jan;57(1):71-78
pubmed: 30489179
Pulm Pharmacol Ther. 2020 Apr;61:101899
pubmed: 31972327
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
J Allergy Clin Immunol. 2017 Jul;140(1):162-169.e2
pubmed: 27826098
Eur Ann Allergy Clin Immunol. 2017 Jul;49(4):171-175
pubmed: 28752720
Allergy Asthma Proc. 2014 May-Jun;35(3):241-9
pubmed: 24801467
Respir Med. 2021 Aug-Sep;185:106491
pubmed: 34098492
J Asthma Allergy. 2022 May 19;15:691-701
pubmed: 35615256
Pulm Pharmacol Ther. 2020 Oct;64:101965
pubmed: 33039667
J Asthma. 2022 Sep;59(9):1796-1804
pubmed: 34348060
Biochem Pharmacol. 2020 Sep;179:113944
pubmed: 32240649
J Asthma Allergy. 2021 Feb 03;14:91-99
pubmed: 33568920
Int Arch Allergy Immunol. 2011;154(1):25-32
pubmed: 20664274
Respir Med. 2019 Mar;148:49-53
pubmed: 30827474
Respir Med. 2017 Mar;124:36-43
pubmed: 28284319
J Asthma Allergy. 2020 May 06;13:159-166
pubmed: 32440161
BMC Pulm Med. 2020 Aug 3;20(1):207
pubmed: 32746787
Int Arch Allergy Immunol. 2003 May;131(1):46-52
pubmed: 12759489